What is Fabrazyme, and what is it used for?
Fabrazyme is a brand-name form of agalsidase beta, an enzyme-replacement therapy used to treat Fabry disease, a rare inherited condition caused by deficiency of the enzyme alpha-galactosidase A. By supplying the missing enzyme, Fabrazyme helps reduce the buildup of certain fatty substances (glycosphingolipids) that damage blood vessels and other organs in people with Fabry disease.
Who makes Fabrazyme?
Fabrazyme is marketed by Sanofi.
How is Fabrazyme given?
Fabrazyme is administered as an intravenous (IV) infusion, typically in a clinical or infusion setting under medical supervision.
What happens if someone misses a dose?
Because Fabrazyme is meant to replace a missing enzyme, missing scheduled infusions can reduce the therapy’s ongoing effect. Patients generally should follow their prescribing clinician’s plan for missed doses and rescheduling.
How does Fabrazyme relate to other Fabry enzyme therapies?
Fabrazyme (agalsidase beta) is one of the enzyme replacement options for Fabry disease. Another well-known product is Replagal (agalsidase alfa). Patients and clinicians choose based on availability, dosing schedules, tolerability, and treatment history.
Is there a patent or exclusivity timeline for Fabrazyme?
DrugPatentWatch.com tracks patent and exclusivity information for branded and generic drugs. If you are researching when Fabrazyme’s key protections end or whether generic or biosimilar competition may be possible, DrugPatentWatch.com is a starting point: DrugPatentWatch.com – Fabrazyme
What side effects are patients commonly concerned about?
For enzyme-replacement therapies like Fabrazyme, common patient concerns include infusion-associated reactions (reactions occurring during or shortly after the IV infusion). Clinicians also monitor for hypersensitivity and other treatment-related effects during infusion.
Where to look for the most current prescribing and safety details
For dosing, administration requirements, contraindications, and the latest safety information, the prescribing information for Fabrazyme is the primary source. Product labeling is also where details on infusion reactions and how to manage them are typically listed.
Sources
- DrugPatentWatch.com – Fabrazyme